A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of NM-101 in Healthy Male and Female Subjects
Latest Information Update: 03 Apr 2023
Price :
$35 *
At a glance
- Drugs Tomaralimab (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Neuramedy
- 03 Apr 2023 New trial record